Session Abstract – PMWC 2022 Silicon Valley

 Session Chair Profile

Ph.D., Founder and CEO, Insilico Medicine, Inc

Biography
Alex Zhavoronkov, PhD, is the founder&CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. He is also the founder of Deep Longevity, developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and insurance industry. Since 2015 he has invented critical technologies in the field of GANs and reinforcement learning for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. He has published over 130 peer-reviewed research papers and 2 books. He serves on the editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and co-chairs the Annual Aging Research,Drug Discovery, and AI Forum.


 Speaker Profile

Ph.D., VP, Global Head In Silico Discovery & External Innovation, Janssen

Biography
Jim Edwards is currently leading a multi-disciplinary group of computational & data scientists providing predictive and design tools across all modalities within the Therapeutics Discovery organization at Janssen, starting at project inception through the identification of clinical candidates. Primary to this, Jim was US Regional Head, Discovery Chemistry at Janssen Research & Development, leading drug discovery teams in South Francisco & La Jolla CA, Boston, MA, and Spring House, PA. These teams were responsible for the design and synthesis of small molecule drug candidates working with partners across DPDS and all six Therapeutic Areas within JRD. From 1999-2014, Jim led various Immunology medicinal chemistry groups at Janssen which delivered clinical-stage molecules against multiple novel first-in-class targets. Jim received his Ph.D. from the University of Illinois, Urbana-Champaign, working with Professor Scott Denmark, and performed post-doctoral studies with Professor Lanny Liebeskind at Emory University.


 Speaker Profile

Ph.D., Vice President, Janssen R&D Strategy and Operations, Johnson & Johnson

Biography
Dr. Tommaso Mansi is currently leading the AI/ML and Digital Health team at the Janssen R&D Data Science division. Dr. Mansi’s focus is on the development of AI solutions that enable deriving actionable insights from multimodal, multiscale data, to support and help accelerate drug discovery and development. Prior to joining Janssen, Dr. Mansi was at Siemens Healthineers, Digital Technology and Innovation. Dr. Mansi’s research interests cover artificial intelligence in healthcare, medical imaging, computational physiology, AI for biology, and image-guided therapy. Dr. Mansi received several awards for his work, gave multiple keynotes at international conferences and events. He holds 60+ granted US patents, co-edited 1 monograph and co-authored 100+ scientific publications.


 Speaker Profile

M.D., DPHIL, CEO, Arctoris Ltd

Biography
Martin-Immanuel Bittner is the CEO of Arctoris, a biotech company combining wet lab automation and machine learning for accelerated small molecule drug discovery. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford, where he co-founded Arctoris. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations, including EACR, AACR, and ESTRO. Martin is a Fellow of the RSA and an elected member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.